Myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement in Vietnam: a case report and literature review

被引：0
|
作者：
Chu, Tan-Huy [1 ,2 ]
Huynh, Thien-Ngon [1 ]
Nguyen, Kim-Son [1 ,2 ]
Phu, Chi-Dung [1 ,2 ]
机构：
[1] Blood Transfus Hematol Hosp, Ho Chi Minh City, Vietnam
[2] Pham Ngoc Thach Univ Med, Ho Chi Minh City, Vietnam
来源：
HEMATOLOGY TRANSFUSION AND CELL THERAPY | 2024年 / 46卷 / 04期
关键词：
8P11; PONATINIB;
D O I：
10.1016/j.htct.2023.04.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：498 / 502
页数：5
相关论文
共 3 条
  • [1] Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement
    Freyer, Craig W.
    Hughes, Mitchell E.
    Carulli, Alison
    Bagg, Adam
    Hexner, Elizabeth
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (04) : 351 - 359
  • [2] Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1
    Patterer, Verena
    Schnittger, Susanne
    Kern, Wolfgang
    Haferlach, Torsten
    Haferlach, Claudia
    ANNALS OF HEMATOLOGY, 2013, 92 (06) : 759 - 769
  • [3] Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR-FGFR1 fusion
    Qiu, Xu-Hua
    Li, Feng
    Cao, Hong-Qin
    Shao, Jing-Jing
    Mei, Jian-Gang
    Li, Han-Qing
    Zhai, Yong-Ping
    MOLECULAR MEDICINE REPORTS, 2017, 15 (03) : 1024 - 1030
1